Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660040 | 0.89 | HPGD (0.33) | LMNAHPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2978063 | 0.89 | LMNA (0.31) | LMNAHPGDMAPTALDH1A1 | |
| SCHEMBL2659944 | 0.88 | LMNA (0.33) | LMNAHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL2976707 | 0.88 | MAPT (0.33) | LMNAHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL2660388 | 0.88 | MAPT (0.33) | HPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2668893 | 0.88 | MAPT (0.33) | HPGDMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2668768 | 0.87 | HPGD (0.34) | LMNAHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL2968130 | 0.87 | ALDH1A1 (0.34) | LMNAHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL2668875 | 0.87 | ALDH1A1 (0.30) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13222228 | 0.86 | MAPT (0.36) | LMNAHPGDMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410087-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | LMNA 4727/4885HPGD 1786/4885MAPT 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.